Langer accepts $450K Kyoto prize; Isis raises $425M; Boehringer passes on Karolinska antibody;

@FierceBiotech: $AMGN and $AZN psoriasis drug beats blockbuster Stelara ($JNJ) in head-to-head trial. Report | Follow @FierceBiotech

@JohnCFierce: Servier gambling up to $1B-plus on Intarcia's PhIII diabetes drug/device. News | Follow @JohnCFierce

@DamianFierce: Hep C market share optimism has $ABBV up. Also, cab ads. Picture | Follow @DamianFierce

> MIT Professor Robert Langer has accepted the prestigious Kyoto Prize, which comes with $450,000. Story

> Isis Pharmaceuticals ($ISIS) priced $425 million in senior notes this morning. Its shares are down 3% in early trading. Release

> In a fresh setback for Karolinska Development, Boehringer Ingelheim has chosen not to exercise its option on Athera Biotechnologies' cardiovascular antibody. Athera is a Karolinska portfolio company. Release

> Australia's Neuren Pharmaceuticals is touting positive Phase II data for Rett syndrome, which sent shares up 53% (or 4 cents, depending on how you're counting). Release (PDF)

Medical Device News

@FierceMedDev: ICYMI yesterday: With fresh infusion of cash in tow, Thync rolls out wearable, noninvasive device to elevate mood. Article | Follow @FierceMedDev

@VarunSaxena2: Aethlon to begin U.S. testing for its Ebola treatment device by year end. More | Follow @VarunSaxena2

@EmilyWFierce: Mark your calendars: EU Commission will decide by Nov. 28 whether or not to approve $MDT's $43B deal for $COV. More  | Follow @EmilyWFierce

> Medtronic borrows $16B to cover rising costs of Covidien deal. Article

> FDA clears first patient-specific spinal rod. More

Pharma News

@FiercePharma: Top-read in #pharma #manufacturing Tues: Dr. Reddy's, Endo benefit from Ranbaxy manufacturing shortfalls. More | Follow @FiercePharma

@EricPFierce: Cadilia gets slapped with #FDA warning for not following up on complaints about stinking APIs. More  | Follow @EricPFierce

@CarlyHFierce: Mylan visits Disney Parks for a little EpiPen marketing magic. More | Follow @CarlyHFierce

> WSJ: Pfizer spinoff Zoetis might be Valeant's backup plan if Allergan bid fails. Story

> Italy, the land of pharma plenty, boasts three hidden billionaires in its ranks. Article

> Winners and losers at AASLD? Check out Merck, AbbVie, Gilead and J&J data. More

Drug Delivery News

> Drug-loaded milk could offer oral HIV/AIDS prevention to children. Story

> Alnylam adds two RNAi programs to its hepatitis pipeline. Article

> Arrowhead's midstage hep B data shows promise for RNA-based 'functional cure.' News

> FDA clears syringe that prevents needlestick injuries. News

> Nasal spray for migraines under development. Story

Diagnostics News

> Study: Myriad skin cancer Dx shows reduction in indeterminate diagnoses. More

> GE Healthcare lends imaging tech to Takeda for Dx partnership. Story

> Quest CEO says 'no' to CRO. Report

> Study: Myriad skin cancer Dx shows reduction in indeterminate diagnoses. More

> GE Healthcare lends imaging tech to Takeda for Dx partnership. Item

> Scientists developing machine-based algorithm for heart failure and emphysema Dx. Article

Pharma Marketing News

> Under siege by Biogen's new long-acting Eloctate, Baxter's Advate stands its ground. Report

> Missing the old pharma swag? Take a trip down memory lane. Article

> Will GLP market growth save Novo's Victoza from Lilly's new Trulicity? More

> Contrave demand swamps Takeda's direct-delivery discount program. Story

> Mylan visits Disney Parks for a little EpiPen marketing magic. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.